GFR slope predicts kidney outcomes in IgA nephropathy beyond static measures. Learn how this could refine trials and risk ...

AstraZeneca announced in May 2026 that its drug Ultomiris significantly reduced urine protein levels in patients with IgA ...

IgA nephropathy (IgAN) is a kidney disorder caused by a buildup of immune complexes and the antibody called immunoglobulin A (IgA) inside the kidneys. This buildup causes inflammation in the kidneys.

The FDA has launched a pilot voucher program to accelerate review of three psychedelic therapies, following a presidential directive prioritizing treatments for serious mental illness, particularly ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Andrew S. Bomback, MD, MPH, comments on the impact of disparities in diagnosing and treating IgA nephropathy by nephrologists. Early detection and treatment of IgA nephropathy are critical for better ...

Researchers have found in a new study that Intraperitoneal (IP) therapy demonstrated better efficacy than MSII in improving ...

Nonperfusion area detected by swept-source optical coherence tomography angiography (OCTA) may predict diabetic nephropathy ...

Diabetic nephropathy is the leading cause of kidney disease in patients starting renal replacement therapy and affects ~40% of type 1 and type 2 diabetic patients. It increases the risk of death, ...

The FDA granted accelerated approval to sparsentan (Filspari) for proteinuria in IgA nephropathy, Travere Therapeutics announced, marking the first non-immunosuppressive therapy for this rare ...

A new pathologic classification scheme for diabetic nephropathy, in which only glomerular lesions are used to classify renal damage associated with either type 1 or type 2 diabetes, has been developed ...